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Biallelic germline mutations in MYH are associated with colorectal neoplasms, which develop through a pathway involving somatic
inactivation of APC. In this study, we investigated the incidence of the common MYH mutations in an Australian cohort of sporadic
colorectal cancers, the clinicopathological features of MYH cancers, and determined whether inactivation of mismatch repair and base
excision repair (BER) were mutually exclusive. The MYH gene was sequenced from lymphocyte DNA of 872 colorectal cancer
patients and 478 controls. Two compound heterozygotes were identified in the cancer population and all three cancers from these
individuals displayed a prominent infiltration of intraepithelial lymphocytes. In total, 11 heterozygotes were found in the cancer group
and five in the control group. One tumour from an individual with biallelic germline mutation of MYH also demonstrated
microsatellite instability (MSI) as a result of biallelic hypermethylation of the MLH1 promoter. Although MYH-associated cancers are
rare in a sporadic colorectal population, this study shows that these tumours can develop through either a chromosomal or MSI
pathway. Tumours arising in the setting of BER or mismatch repair deficiency may share a biological characteristic, which promotes
lymphocytic infiltration.
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MYH-associated polyposis (MAP) is an autosomal recessive
condition (Al-Tassan et al, 2002) associated with the development
of multiple adenomas and carcinomas of the colon and rectum, as
well as other possible malignancies and extra-colonic manifesta-
tions (Enholm et al, 2003; Sampson et al, 2003; Sieber et al, 2003;
Gismondi et al, 2004; Nielsen et al, 2005). The syndrome is caused
by germline biallelic mutations in MYH, a gene that codes for a
DNA glycosylase involved in base excision repair (BER) (Al-Tassan
et al, 2002). MYH mutations have been shown to be ethnically
specific, and most (80%) Caucasian individuals with MAP possess
the Y165C or G382D mutations (Enholm et al, 2003; Croitoru et al,
2004; Fleischmann et al, 2004; Wang et al, 2004; Farrington et al,
2005; Peterlongo et al, 2005). Italian populations also carry a three
base pair deletion (1395delGGA) in exon 14 (Gismondi et al, 2004),
whereas non-Caucasian populations harbour a range of different
MYH mutations (Jones et al, 2002). As MAP is a recessive
condition, patients may appear to have sporadic, rather than
familial, colorectal cancer. However, a number of studies have
shown that biallelic mutations in MYH account for only a minority
of sporadic colorectal cancers (Enholm et al, 2003; Croitoru et al,
2004; Fleischmann et al, 2004; Wang et al, 2004; Farrington et al,
2005; Peterlongo et al, 2005). The significance of heterozygous
MYH mutations in terms of cancer risk remains uncertain.
MYH-associated cancers are thought to progress through a
distinct genetic pathway which does not involve microsatellite
instability (MSI) (Lipton et al, 2003). Supporting this hypothesis,
MYH cancers have an increased frequency of somatic transversion
mutations of APC and K-ras (Al-Tassan et al, 2002; Jones et al,
2002; Lipton et al, 2003; Jones et al, 2004), although no
pathologically distinctive features have been described to date.
In this study, we utilised a large and well-characterised tumour
bank of sporadic colorectal cancers to investigate the clinico-
pathological features of MYH cancers, and to determine whether
mismatch repair and base excision repair are mutually exclusive.
MATERIALS AND METHODS
Patients and specimens
This study was performed with the approval of the St Vincent’s
Human Research Ethics Committee. After obtaining informed
consent, 872 individuals undergoing complete (RO or R1) surgical
resection of 893 colorectal cancers at St Vincent’s Hospital,
Sydney, were entered in this prospective study (Ward et al, 2005).
The study population consisted of 402 female and 470 male
subjects with a mean age of 69.2712.1 years (range 29–99 years).
Enrolment was from 1 January 1994 to 29 May 2004, and patients
presenting for resection of cancer in the setting of known
inflammatory bowel disease, FAP and HNPCC were not enrolled.
Peripheral blood was also collected from 284 male and 194 female
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shealthy blood donors (Red Cross Blood Bank, Sydney), with a
mean age of 45714 years.
Tumour stage was assessed according to AJCC/UICC guidelines
and histopathological characteristics were determined as pre-
viously described (Ward et al, 2005). Microsatellite status was
determined using primer sets for Bat 25, Bat 26, Bat 40, D5S346,
D2S123 and D17S250, and tumours with instability at two or more
markers were classified as microsatellite unstable, the remainder
being categorised as microsatellite stable (Ward et al, 2005).
Immunohistochemistry for the mismatch repair proteins and p53
was performed as previously described (Ward et al, 2005).
MYH mutation analysis
To identify the common ‘Caucasian’ pathogenic MYH mutations,
exons 7, 13 and 14 of MYH were amplified and sequenced from
lymphocyte DNA using previously designed primers (Gismondi
et al, 2004; Kairupan et al, 2005). The Y165C (exon 7) and
1395delGGA (exon 14) mutations were confirmed by sequencing
the complementary strand, and the G382D (exon 13) mutation was
verified using a restriction enzyme digest (BglII). The remaining
MYH exons were then sequenced in those individuals who were
heterozygotes for one of the common mutations. Briefly, exon-
specific primers ((Gismondi et al, 2004; Kairupan et al, 2005)
additional details available on request) were used to amplify the 16
exons of MYH in 25ml reactions containing 100ng of genomic
DNA, 0.4mM of each of the primer, 0.2mM of dNTP, 1U of FastStart
Taq polymerase and a PCR master mix at 1.5mM MgCl2. The PCR
products were purified using the QIAquick PCR purification kit
(Qiagen, Basel, Switzerland) and sequencing was performed using
the Big Dye Terminator Cycle Sequencing kit (Applied Biosystems,
Rotkreuz, Switzerland). Purified sequence reactions were separated
on the ABI3100 Genetic Analyser (Applied Biosystems), and the
nucleotide sequences analysed with the aid of the Sequencher
software program (Gene Codes Corporation, Ann Arbor, MI,
USA).
Methylation analysis of MLH1 promoter
DNA (1–2mg) was converted with sodium bisulphite and the ‘A’
and ‘C’ regions of the MLH1 promoter were subject to combined
bisulphite restriction analyses (COBRA) as previously described
(Hitchins et al, 2005). Samples giving a positive restriction
digestion pattern indicative of the presence of methylation were
cloned into the pGEMTeasy vector (Promega, Annandale, NSW,
Australia), and individual clones were fluorescently sequenced on
an ABI 3100 using SP6 and T7 vector primers.
Statistical analysis
Categorical variables were compared using the w
2-test or Fisher’s
exact test as appropriate. In patients with more than one cancer,
only the properties of the most advanced tumour were considered
in the case control study. All tumours were considered when
analysing tumour properties. A probability value of less than 0.05
was considered significant. All data were analysed using the SPSS
statistical software V13.0 (SPSS Inc., Chicago, IL, USA).
RESULTS
Frequency and spectrum of MYH mutations
Of the 872 individuals with colorectal cancer, two were compound
heterozygotes (patient 9033 and 13714) and a further 11 had a
monoallelic mutation in MYH (Table 1). None of the 478 control
individuals harboured biallelic MYH mutations, but five were
found to be heterozygotes (Table 1). After sequencing the
remaining exons in the 16 heterozygotes, a number of nonpatho-
genic missense mutations were identified (one V22M, five Q324H
and one S501F). No significant difference in the frequency of
biallelic (P¼0.542, Fisher’s exact test) or monoallelic MYH
mutations (w
2¼0.12, P¼0.72) was found between the colorectal
and the control groups.
Pathological features of tumours in MYH mutation
carriers
At the time of surgical resection, one compound heterozygote
(patient 9033) was found to have synchronous stage III colorectal
cancers as well as more than 100 adenomatous polyps scattered
throughout the colon. The clinicopathological characteristics of
these cancers, as well as the stage III caecal cancer from individual
13714 (G382D/1395delGGA) are shown in Table 2. Both of these
individuals harboured multiple adenomatous polyps; however the
only manifestation of extra-colonic disease was in patient 9033,
who had a history of malignant melanoma at the age of 28 years.
Interestingly, the three cancers from these individuals displayed a
prominent infiltration of intraepithelial lymphocytes.
In most respects, cancers arising in monoallelic MYH carriers
were indistinguishable from cancers arising in individuals in
whom no MYH mutations had been identified (Table 2). A
statistically significant increase in the number of intraepithelial
lymphocytes was noted in the heterozygote mutation group
compared with the rest of the colorectal cohort (five of 11 vs 151
of 827 assessable cases, P¼0.04, Fisher’s Exact test). However, this
association was probably a reflection of the microsatellite status of
the cancer, as all but one case with prominent intraepithelial
lymphocytes was associated with a microsatellite unstable cancer.
Microsatellite instability and MYH mutations
The frequency of tumours with microsatellite instability arising in
cases with MYH mutations is shown in Table 2. Of the 893 tumours
assessed for MSI in this study, 139 (15.5%) showed MSI.
Individuals who were heterozygous for an MYH mutation were
Table 1 List of MYH mutations and polymorphisms in the colorectal
cohort and the control group
ID Age Gender MYH mutations Polymorphism
Colorectal patients
Biallelic (n¼2)
9033 50 F Y165C G382D NT
13714 60 M G382D 1395delGGA NT
Monoallelic (n¼11)
15311 77 F Y165C
11408 88 F G382D
10355 76 M Y165C
13122 72 M G382D Q324H
11358 44 M G382D Q324H
13911 81 F G382D
14359 70 M G382D
11913 88 F G382D
14838 64 F Y165C Q324H, S501F
511 74 F G382D
11328 65 F G382D
Controls
Monoallelic (n¼5)
69 M G382D Q324H
54 M G382D Q324H
62 F Y165C V22M
31 M G382D
58 M G382D
NT¼not tested; M¼male; F¼female.
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smore likely to have an MSI tumour (five of 11, w
2 test Po0.01),
whereas one of the cancers seen in the two individuals with
biallelic MYH mutations was also MSI (Table 2). This individual
(9033) had a microsatellite unstable caecal cancer which failed to
express the mismatch repair protein MLH1 by immunohisto-
chemistry, as well as a rectal cancer that was microsatellite stable
and expressed the mismatch repair proteins MLH1, MSH2 and
MSH6. The microsatellite unstable caecal cancer did not display
the typical pathological features of a sporadic MSI colorectal
cancer, in that it was nonmucinous, of low histological grade and
BRAF mutation negative (data not shown). The pedigree and
results of MYH mutation testing in this family is shown in Figure 1,
panel A. Germline testing of the mismatch repair genes failed to
identify a pathogenic mutation in individual 9033.
To determine the mechanism of inactivation of MLH1 in the
caecal cancer of patient 9033, we subjected the MLH1 promoter to
bisulphite sequencing. As patient 9033 was heterozygous for the
A/G polymorphism (rs11800734) in the MLH1 promoter, bisul-
phite sequencing was able to confirm methylation of both alleles in
the tumour cells (Figure 1B). Unmethylated A and G alleles were
Table 2 Clinicopathological features of individuals with germline MYH mutations
Patient ID Adenomas Cancer site Stage Grade Mucin IELs P53 IHC MSI
Biallelic mutation carriers
13714 Seven TA, One HP Caecum III Low No Yes Neg MSS
9033 Caecal carpet Caecum III Low No Yes Neg MSI
4100 adenomas Rectum III Low Yes Yes Pos MSS
Monoallelic mutation carriers
15311 No Caecal II Low No No MSI
11408 NS AC II Low No Yes Neg MSS
10355 No DC II High Yes Yes Neg MSI
13122 No Caecum I High No Yes MSI
11358 No Rectum III Low No No Neg MSS
13911 No Caecum II Low No No Neg MSS
14359 No TC II Low Yes Yes MSI
11913 Yes Caecum II Low No Yes Neg MSI
14838 No AC IV Low No No MSS
511 NS Rectum III Low No No Pos MSS
11328 No SC II Low No No Neg MSS
MSS¼microsatellite stable; MSI¼microsatellite instability; IELs¼prominent intraepithelial lymphocytes (46 per high-power field); TA¼tubular adenoma; HP¼hyperplastic
polyp; AC¼ascending colon; TC¼transverse colon; DC¼descending colon; SC¼sigmoid colon.
Het Y165C Het G382D
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Figure 1 (A) Pedigree showing the family of the proband (case 9033, marked with black arrow) and their respective disease and mutation status. WT,
wild type; left half shaded black, polyps; right half shaded black, cancer. (B) Schematic of promoter region of MLH1 from the caecal tumour from case 9033
demonstrating biallelic methylation. Each allele is distinguished by the presence of an SNP (coloured square). Circles represent CpG islands, filled circles
represent methylation, the blue square represents guanine and the red square represents adenine. (C) Sequence traces obtained from the caecal tumour of
case 9033 demonstrate the presence of biallelic MYH mutations. The patient was compound heterozygote for the Y165C and G382D mutations.
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spresumably derived from contaminating normal tissue, thus
suggesting that normal somatic colonic cells were unmethylated.
Microdissected tumour tissue was then subjected to genetic
analysis for MYH mutations. As expected, the tumour displayed
the missense mutations Y165C and G382D (Figure 1C), thus
confirming that this carcinoma possessed MSI in the context of
biallelic MYH mutations.
DISCUSSION
This study shows that biallelic MYH mutations are rare (0.2%,
2/872) in an Australian colorectal cancer population. It must be
acknowledged that the screening strategy used in this study
examined exons 7, 13 and 14 of MYH. While these regions account
for around 80% of known mutations in Caucasians, a small
number of pathogenic mutations will have been missed because of
this approach. Nevertheless, this mutation frequency was compar-
able to studies from Finland (0.4%, four out of 1042) (Enholm et al,
2003), North America (0.4%, two out of 555 and two out of 444,
0.5%) (Wang et al, 2004; Peterlongo et al, 2005), Canada (1.0%,
12 out of 1238) (Croitoru et al, 2004), Scotland (0.5%, 12/
2239)(Farrington et al, 2005) and Britain (0.3%, one out of 358)
(Fleischmann et al, 2004). Like other studies, we found a lower
frequency of the Y165C allele (0.2% in cases and 0.1% in controls)
than the G382D allele (0.6% in cases and 0.4% in controls). Given
the significant number of southern European migrants resident in
Australia, it is surprising that only one individual was identified
with an exon 14 mutation (135delGGA) (Gismondi et al, 2004).
While others have suggested that the frequency mutations in exon
14 such as A459T justify routine mutation screening of this exon,
our data does not support this position, at least in a nonpolyposis
population (Alhopuro et al, 2005).
Lipton et al (2003) proposed that carcinomas arising in the
setting of biallelic MYH mutations followed a distinct genetic
pathway. If this hypothesis was correct, a distinctive clinicopatho-
logical phenotype may accompany the development of MYH-
related cancers. Although we found little evidence to support this
suggestion, it was interesting that the three cancers arising in the
individuals with biallelic mutations in MYH displayed a prominent
infiltration of intraepithelial lymphocytes. Lymphocytic infiltrates
are strongly associated with the development of mismatch repair-
deficient cancers, although a proportion of microsatellite stable
tumours also demonstrate intraepithelial lymphocytes (Ward et al,
2001). The mechanism for recruitment of lymphocytes in these
cancers is unknown (Quinn et al, 2003), but mutator and DNA
repair phenotypes may share properties which favour the retention
of lymphocytes in the epithelium. The phenomenon of increased
lymphocytic infiltration in MSI tumours has been suggested as a
possible reason for the improved survival seen in these cancers
(Guidoboni et al, 2001). It is possible that MAP cancers represent a
subgroup of MSS cancers that may also share this improved
prognosis.
Significantly, our study has also shown that MSI cancers can
arise in the setting of biallelic germline MYH mutations, and that
MSI cancers may arise more commonly in individuals with
monoallelic MYH germline mutation than in normal individuals.
To date, the 168 MAP tumours (includes 48 colorectal cancers)
reported in the literature were microsatellite stable (Lipton et al,
2003; Fleischmann et al, 2004; Wang et al, 2004; Nielsen et al,
2005). This is expected given that mutations of MYH predisposes
to inactivation of APC through G:C to A:T transversions
(Al-Tassan et al, 2002). The absence of MSI in MAP carcinomas
led to the suggestion that the derangement of both base excision
repair and mismatch repair was not compatible with cellular
survival (Kambara et al, 2004). The case of an MSI cancer in the
setting of MYH biallelic germline mutation reported in our
study clearly does not support this hypothesis, and it is interesting
that MLH1 was inactivated by biallelic promoter methylation,
rather than through somatic mutations secondary to loss of
MYH function. In this case, it is apparent that biallelic MYH
mutations have played a role in the early stages of colorectal
carcinogenesis through APC mutation and polyp formation. Yet,
this influence has been superseded by the tumorigenic drive
provided by loss of MLH1 function. It is possible that MYH
mutations may have a largely permissive role in tumorigenesis
through polyp formation, with subsequent progression occurring
as a result of changes to other key genes. This role of MYH
mutations in colorectal carcinogenesis is consistent with the
finding in murine models that MYH knockouts are phenotypically
normal (Xie et al, 2004).
It is also worth noting that patient 9033 was only 50 years of age.
This is a strikingly young age for the development of a ‘sporadic’
MSI cancer through biallelic methylation of MLH1 (Ward et al,
2001), and raises the possibility that MYH mutation has somehow
either facilitated methylation, or acted synergistically with MLH1
loss to more rapidly drive tumour progression. A more testable
implication is that MYH mutation may be worth considering in
younger individuals with MSI tumours that have developed
because of MLH1 methylation. Such individuals are increasingly
likely to be recognised because of immunohistochemical testing of
colorectal cancers. Biallelic MYH mutation remains an uncommon
event, and the small numbers of cases in this report allow us only
to speculate on the biological relevance in a sporadic population.
More systematic studies of MYH status in distinct populations will
be required to properly evaluate the true significance of MYH loss
in colorectal carcinogenesis.
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